BACKGROUND: A Phase I trial of the 2-drug regimen of everolimus plus gemcitabine (Cohort I) and the 3-drug regimen of everolimus plus gemcitabine and cisplatin (Cohort II) was performed to determine the maximally tolerated dose (MTD) of both combinations. An expansion cohort (Cohort III) of patients with cholangiocarcinoma or gallbladder carcinoma was treated at the MTD. METHODS: A standard 3 + 3 design dose escalation was used. Everolimus was given on Monday/Wednesday/Friday or daily depending upon the dose level. Gemcitabine and cisplatin were administered on days 1 and 8 of each 21 day cycle. RESULTS: Twelve patients were entered in Cohort I and 15 in Cohort II. The MTD for Cohort I was everolimus 5 mg on Monday/Wednesday/Friday and gemcitabine 800 mg/m(2). For Cohort II, it was everolimus 5 mg on Monday/Wednesday/Friday, gemcitabine 600 mg/m(2), and cisplatin 12.5 mg/m(2). All DLTs in this study were hematologic. Complete responses (CR) were seen in a patient with primary peritoneal carcinoma and another with recurrent pancreatic cancer. Partial responses (PR) were seen in 3 patients: breast, ampullary carcinoma and pheochromocytoma. Of 10 patients enrolled in Cohort III, six patients had stable disease and 4 had progressive disease. CONCLUSIONS: This Phase I clinical trial has demonstrated that these 2-drug and 3-drug combinations are generally well tolerated and safely administered. The main DLTs in both regimens were hematologic, specifically thrombocytopenia. The 3-drug combination can be considered as a platform for future studies in specific tumor types.
BACKGROUND: A Phase I trial of the 2-drug regimen of everolimus plus gemcitabine (Cohort I) and the 3-drug regimen of everolimus plus gemcitabine and cisplatin (Cohort II) was performed to determine the maximally tolerated dose (MTD) of both combinations. An expansion cohort (Cohort III) of patients with cholangiocarcinoma or gallbladder carcinoma was treated at the MTD. METHODS: A standard 3 + 3 design dose escalation was used. Everolimus was given on Monday/Wednesday/Friday or daily depending upon the dose level. Gemcitabine and cisplatin were administered on days 1 and 8 of each 21 day cycle. RESULTS: Twelve patients were entered in Cohort I and 15 in Cohort II. The MTD for Cohort I was everolimus 5 mg on Monday/Wednesday/Friday and gemcitabine 800 mg/m(2). For Cohort II, it was everolimus 5 mg on Monday/Wednesday/Friday, gemcitabine 600 mg/m(2), and cisplatin 12.5 mg/m(2). All DLTs in this study were hematologic. Complete responses (CR) were seen in a patient with primary peritoneal carcinoma and another with recurrent pancreatic cancer. Partial responses (PR) were seen in 3 patients: breast, ampullary carcinoma and pheochromocytoma. Of 10 patients enrolled in Cohort III, six patients had stable disease and 4 had progressive disease. CONCLUSIONS: This Phase I clinical trial has demonstrated that these 2-drug and 3-drug combinations are generally well tolerated and safely administered. The main DLTs in both regimens were hematologic, specifically thrombocytopenia. The 3-drug combination can be considered as a platform for future studies in specific tumor types.
Authors: Terry O'Reilly; Paul M J McSheehy; Markus Wartmann; Peter Lassota; Ralf Brandt; Heidi A Lane Journal: Anticancer Drugs Date: 2011-01 Impact factor: 2.248
Authors: J M Kovarik; H D Sabia; J Figueiredo; H Zimmermann; C Reynolds; S C Dilzer; K Lasseter; C Rordorf Journal: Clin Pharmacol Ther Date: 2001-11 Impact factor: 6.875
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: S Okada; H Ishii; H Nose; M Yoshimori; T Okusaka; K Aoki; M Iwasaki; J Furuse; M Yoshino Journal: Oncology Date: 1994 Nov-Dec Impact factor: 2.935
Authors: Anne O'Donnell; Sandrine Faivre; Howard A Burris; Daniel Rea; Vassiliki Papadimitrakopoulou; Nicholas Shand; Heidi A Lane; Katharine Hazell; Ulrike Zoellner; John M Kovarik; Cathryn Brock; Suzanne Jones; Eric Raymond; Ian Judson Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: Chiaki Tanaka; Terence O'Reilly; John M Kovarik; Nicholas Shand; Katharine Hazell; Ian Judson; Eric Raymond; Sabine Zumstein-Mecker; Christine Stephan; Anne Boulay; Marc Hattenberger; George Thomas; Heidi A Lane Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: Tamás Sticz; Anna Molnár; Titanilla Dankó; Zoltán Hujber; Gábor Petővári; Noémi Nagy; Gyula Végső; László Kopper; Anna Sebestyén Journal: Pathol Oncol Res Date: 2018-06-07 Impact factor: 3.201
Authors: Robert R McWilliams; Jacob B Allred; Jessica A Slostad; Rajini Katipamula; Roxana S Dronca; Kandelaria M Rumilla; Lori A Erickson; Alan H Bryce; Richard W Joseph; Lisa A Kottschade; David M King; John M Leitch; Svetomir N Markovic Journal: Cancer Date: 2017-10-17 Impact factor: 6.860
Authors: S Calabretta; P Bielli; I Passacantilli; E Pilozzi; V Fendrich; G Capurso; G Delle Fave; C Sette Journal: Oncogene Date: 2015-08-03 Impact factor: 9.867